Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent

Sanhita Sinharay, Christine M. Howison, Amanda F Baker, Mark "Marty" Pagel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis. The monitoring of uPA activity using molecular imaging may have prognostic value and be predictive for response to anti-cancer therapies. However, the detection of in vivo enzyme activity with molecular imaging remains a challenge. To address this problem, we designed a nonmetallic contrast agent, GR-4Am-SA, that can be detected with chemical exchange saturation transfer (CEST) MRI. This agent has a peptide that is cleaved by uPA, which causes a CEST signal at 5.0 ppm to decrease, and also has a salicylic acid moiety that can produce a CEST signal at 9.5 ppm, which is largely unresponsive to enzyme activity. The two CEST signals were used to determine a reaction coordinate, representing the extent of enzyme-catalyzed cleavage of the GR-4Am-SA agent during an experimental study. Initial biochemical studies showed that GR-4Am-SA could detect uPA activity in reducing conditions. Subsequently, we used our catalyCEST MRI protocol with the agent to detect the uPA catalysis of GR-4Am-SA in a flank xenograft model of Capan-2 pancreatic cancer. The results showed an average reaction coordinate of 80% ± 8%, which was strongly dependent on the CEST signal at 5.0 ppm. The relative independence of the reaction coordinate on the CEST signal at 9.5 ppm showed that the detection of enzyme activity was largely independent of the concentration of GR-4Am-SA within the tumor tissue. These results demonstrated the advantages of a single CEST agent with biomarker-responsive and unresponsive signals for reliably assessing enzyme activity during in vivo cancer studies.

Original languageEnglish (US)
Article numbere3721
JournalNMR in Biomedicine
Volume30
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Magnetic resonance imaging
Contrast Media
Enzyme activity
Enzymes
Molecular Imaging
Molecular imaging
Neoplasms
Tumors
Salicylic Acid
Catalysis
Pancreatic Neoplasms
Heterografts
Biomarkers
Neoplasm Metastasis
Peptides
Tissue
Monitoring

Keywords

  • CEST MRI
  • enzyme activity
  • pancreatic cancer
  • urokinase plasminogen activator

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Spectroscopy

Cite this

Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent. / Sinharay, Sanhita; Howison, Christine M.; Baker, Amanda F; Pagel, Mark "Marty".

In: NMR in Biomedicine, Vol. 30, No. 7, e3721, 01.07.2017.

Research output: Contribution to journalArticle

@article{3f3d5b7bd33c43e8bf67221258cb949a,
title = "Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent",
abstract = "Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis. The monitoring of uPA activity using molecular imaging may have prognostic value and be predictive for response to anti-cancer therapies. However, the detection of in vivo enzyme activity with molecular imaging remains a challenge. To address this problem, we designed a nonmetallic contrast agent, GR-4Am-SA, that can be detected with chemical exchange saturation transfer (CEST) MRI. This agent has a peptide that is cleaved by uPA, which causes a CEST signal at 5.0 ppm to decrease, and also has a salicylic acid moiety that can produce a CEST signal at 9.5 ppm, which is largely unresponsive to enzyme activity. The two CEST signals were used to determine a reaction coordinate, representing the extent of enzyme-catalyzed cleavage of the GR-4Am-SA agent during an experimental study. Initial biochemical studies showed that GR-4Am-SA could detect uPA activity in reducing conditions. Subsequently, we used our catalyCEST MRI protocol with the agent to detect the uPA catalysis of GR-4Am-SA in a flank xenograft model of Capan-2 pancreatic cancer. The results showed an average reaction coordinate of 80{\%} ± 8{\%}, which was strongly dependent on the CEST signal at 5.0 ppm. The relative independence of the reaction coordinate on the CEST signal at 9.5 ppm showed that the detection of enzyme activity was largely independent of the concentration of GR-4Am-SA within the tumor tissue. These results demonstrated the advantages of a single CEST agent with biomarker-responsive and unresponsive signals for reliably assessing enzyme activity during in vivo cancer studies.",
keywords = "CEST MRI, enzyme activity, pancreatic cancer, urokinase plasminogen activator",
author = "Sanhita Sinharay and Howison, {Christine M.} and Baker, {Amanda F} and Pagel, {Mark {"}Marty{"}}",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/nbm.3721",
language = "English (US)",
volume = "30",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent

AU - Sinharay, Sanhita

AU - Howison, Christine M.

AU - Baker, Amanda F

AU - Pagel, Mark "Marty"

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis. The monitoring of uPA activity using molecular imaging may have prognostic value and be predictive for response to anti-cancer therapies. However, the detection of in vivo enzyme activity with molecular imaging remains a challenge. To address this problem, we designed a nonmetallic contrast agent, GR-4Am-SA, that can be detected with chemical exchange saturation transfer (CEST) MRI. This agent has a peptide that is cleaved by uPA, which causes a CEST signal at 5.0 ppm to decrease, and also has a salicylic acid moiety that can produce a CEST signal at 9.5 ppm, which is largely unresponsive to enzyme activity. The two CEST signals were used to determine a reaction coordinate, representing the extent of enzyme-catalyzed cleavage of the GR-4Am-SA agent during an experimental study. Initial biochemical studies showed that GR-4Am-SA could detect uPA activity in reducing conditions. Subsequently, we used our catalyCEST MRI protocol with the agent to detect the uPA catalysis of GR-4Am-SA in a flank xenograft model of Capan-2 pancreatic cancer. The results showed an average reaction coordinate of 80% ± 8%, which was strongly dependent on the CEST signal at 5.0 ppm. The relative independence of the reaction coordinate on the CEST signal at 9.5 ppm showed that the detection of enzyme activity was largely independent of the concentration of GR-4Am-SA within the tumor tissue. These results demonstrated the advantages of a single CEST agent with biomarker-responsive and unresponsive signals for reliably assessing enzyme activity during in vivo cancer studies.

AB - Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis. The monitoring of uPA activity using molecular imaging may have prognostic value and be predictive for response to anti-cancer therapies. However, the detection of in vivo enzyme activity with molecular imaging remains a challenge. To address this problem, we designed a nonmetallic contrast agent, GR-4Am-SA, that can be detected with chemical exchange saturation transfer (CEST) MRI. This agent has a peptide that is cleaved by uPA, which causes a CEST signal at 5.0 ppm to decrease, and also has a salicylic acid moiety that can produce a CEST signal at 9.5 ppm, which is largely unresponsive to enzyme activity. The two CEST signals were used to determine a reaction coordinate, representing the extent of enzyme-catalyzed cleavage of the GR-4Am-SA agent during an experimental study. Initial biochemical studies showed that GR-4Am-SA could detect uPA activity in reducing conditions. Subsequently, we used our catalyCEST MRI protocol with the agent to detect the uPA catalysis of GR-4Am-SA in a flank xenograft model of Capan-2 pancreatic cancer. The results showed an average reaction coordinate of 80% ± 8%, which was strongly dependent on the CEST signal at 5.0 ppm. The relative independence of the reaction coordinate on the CEST signal at 9.5 ppm showed that the detection of enzyme activity was largely independent of the concentration of GR-4Am-SA within the tumor tissue. These results demonstrated the advantages of a single CEST agent with biomarker-responsive and unresponsive signals for reliably assessing enzyme activity during in vivo cancer studies.

KW - CEST MRI

KW - enzyme activity

KW - pancreatic cancer

KW - urokinase plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=85016720758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016720758&partnerID=8YFLogxK

U2 - 10.1002/nbm.3721

DO - 10.1002/nbm.3721

M3 - Article

C2 - 28370884

AN - SCOPUS:85016720758

VL - 30

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 7

M1 - e3721

ER -